Because the effect of DYRK1A inhibition on cell proliferation is controversial and cellular context dependent (Fernandez‐Martinez et al, 2015), a broad range of anti‐proliferative activity of T‐025 also supports our hypothesis that contributions of DYRK1A inhibition on the effects of T‐025 are limited and a small molecule inhibitor of CLK has therapeutic potential for cancer. The gene discussed is CLK1; the disease is cancer.